Stay updated with breaking news from Jean Bourhis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oncology company Oxford BioTherapeutics has announced that the first patient has been dosed in a phase 1b trial investigating its lead candidate OBT076, in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck.
High-energy electron beams may be able to kill tumors 10 times deeper than current treatments can—without damaging vital organs.
/PRNewswire/ -- The Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, the European Laboratory for Particle Physics (CERN) and THERYQ...
LAUSANNE, Switzerland, and PEYNIER, France, Nov. 25, 2022 /PRNewswire/ -- The Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, the European Laboratory for Particle Physics
Lausanne, Switzerland, Nov 25 (EFE).- A new cancer treatment that will harness CERN research on very high-energy electrons to target deep lying tumors resistant to conventional therapies was presented Friday at a Swiss hospital with hopes that it could be rolled out by 2025. The revolutionary FLASH radiotherapy treatment is the result of a tripartite …